MyoKardia
MyoKardia is a company based in San Francisco, United States.
Last updated September 15, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
MyoKardia is a company located in San Francisco, United States. Available evidence confirms only its identity and location; no further brand history, ownership, products, or activities are supported by the supplied sources.
History
MyoKardia is identified in the available evidence as a company in San Francisco, United States. The supplied sources do not provide further details about its history, founding, ownership, or operations.
Recent events
Reported
Bristol Myers Squibb completes acquisition of MyoKardia[2]
Bristol Myers Squibb completed its $13.1 billion acquisition of MyoKardia, gaining rights to MyoKardia’s investigational treatment mavacamten and its cardiovascular drug pipeline.
Reported
LianBio licenses drug programs for China and selected Asian markets[3]
LianBio launched with three assets licensed from MyoKardia and BridgeBio Pharma companies Navire Pharma and QED Therapeutics. In exchange, LianBio agreed to pay more than $60 million upfront for development and commercialization rights in China and selected Asian markets; the article also reports a $26.5 million upfront payment for infigratinib.
Reported
MyoKardia reports third-quarter 2019 financial results[4]
MyoKardia reported financial results for the quarter ended September 30, 2019, including a net loss of $141.8 million for the quarter.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/myokardia-united-states · Editorial policy · How profiles are compiled